Peter Greenleaf
2019 - Avalo Therapeutics
In 2019, Peter Greenleaf earned a total compensation of $735.2K as Former Chief Executive Officer and former Principal Executive Officer at Avalo Therapeutics, a 86% decrease compared to previous year.
Compensation breakdown
| Salary | $175,750 |
|---|---|
| Other | $559,454 |
| Total | $735,204 |
Greenleaf received $559.5K in other compensation, accounting for 76% of the total pay in 2019.
Greenleaf also received $175.8K in salary.
Rankings
In 2019, Peter Greenleaf's compensation ranked 10,530th out of 13,971 executives tracked by ExecPay. In other words, Greenleaf earned more than 24.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,530 out of 13,971 | 25th |
Division Manufacturing | 4,255 out of 5,695 | 25th |
Major group Chemicals And Allied Products | 1,646 out of 2,194 | 25th |
Industry group Drugs | 1,409 out of 1,880 | 25th |
Industry Pharmaceutical Preparations | 1,044 out of 1,392 | 25th |
Source: SEC filing on April 28, 2020.
Greenleaf's colleagues
We found three more compensation records of executives who worked with Peter Greenleaf at Avalo Therapeutics in 2019.
News
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2021 pay falls 88% to $1.2M
April 18, 2022
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2020 pay jumps 1,353% to $11M
May 10, 2021
Avalo Therapeutics Chairman Simon Pedder's 2019 pay jumps 13,562% to $3.8M
April 28, 2020
Avalo Therapeutics CEO Peter Greenleaf's 2018 pay jumps 17,372% to $5.1M
June 19, 2019